In a xenograft model, it was shown that implantation of CD133-positive glioma cells results in the development of intracranial tumors [5] and that these cells are resistant to radiation as well as temozolomide as the standard chemotherapeutic compound in GBM therapy [7, 8]. This evidence concerns the gene PROM1 and central nervous system cancer.